Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06808516 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls

Study acronym: OxyPLEASURE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 2025 to Jul 1, 2025
    • Site details revised
    v4
  2. Start date: Apr 2025 to May 2025v3
  3. Start date: Feb 2025 to Apr 2025v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study aims to investigate whether intranasal oxytocin (OXT) improves sexual well-being in patients with Arginine Vasopressin Deficiency (AVP-D). The trial consists of two parts: Part A assesses the effect of OXT on sexual well-being and intimacy over a 7-day treatment period in participants in a stable partnership. Part B assesses the effect of a single dose OXT on sexual arousal, fear and empathy in a clinical setting and is designed for single participants and those in partnerships.
Trial Details
NCT Number NCT06808516
Lead Sponsor University Hospital, Basel, Switzerland
Conditions
(from sponsor)		 Arginine Vasopressin Deficiency, Central Diabetes Insipidus, Oxytocin Deficiency
Related terms Diabetes Insipidus, Neurogenic
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov